A nattokinase bottle marked 4,000 FU looks easy to compare with one marked 2,000 FU. Twice the number must mean twice the result—right? Not necessarily. The number describes enzyme activity in a laboratory assay. It does not, by itself, describe what will happen after someone swallows the product.
Human studies make that distinction especially important. The same 2,000-FU daily amount has been tested in a short blood-pressure trial and a three-year trial with different participants and different findings. Higher amounts appear in other studies, but those studies cannot simply be arranged into a reliable personal dosing chart.
Quick answer: FU measures fibrinolytic activity under laboratory test conditions. It is not a measurement of benefit inside your body. Current evidence does not establish a dependable rule assigning 2,000, 4,000, or a higher number of FU to a particular type of person.
This article explains research and labels; it is not a personal dosing plan. The product examples illustrate labeled activity amounts, not products tested in the cited trials or recommendations for those amounts. Sources, manufacturer specifications, and product-page details were checked on October 5, 2026.
1. What Does FU Actually Measure?
Nattokinase is an enzyme associated with natto, the Japanese fermented-soybean food. FU stands for fibrinolytic units. A 2023 systematic review describes the unit as a way to quantify nattokinase's ability to break down fibrin in vitro—outside a living body, under laboratory conditions. [1]
That makes FU different from milligrams. Milligrams describe mass; FU describes measured activity. There is no universal conversion from milligrams to FU without knowing the activity of the particular preparation. Neither number alone establishes an absorbed amount, a clinical result, or an appropriate personal intake.
Swipe to compare →
| Number or detail | What it describes | What it cannot establish |
|---|---|---|
| 2,000 or 4,000 FU | Reported fibrinolytic activity in an assay | An individual clinical benefit or an optimal dose |
| Milligrams of extract | Mass of the listed preparation | FU without a preparation-specific activity value |
| FU per serving | Activity attributed to the complete labeled serving | Activity per capsule unless serving size is known |
| Package count | Tablets or softgels in the container | Daily activity or effectiveness |
| A study's daily amount | The regimen used with that study's participants | The amount another person should take |
For preparations assessed on the same assay basis, 4,000 FU represents twice the reported activity of 2,000 FU. That arithmetic does not demonstrate twice the absorption, twice the benefit, or a better choice for someone with a particular health concern. Also check whether the label qualifies when activity was measured, such as “at the time of manufacture.”
2. The Same 2,000 FU, Two Very Different Trials
Two placebo-controlled studies illustrate why “a dose used in research” is not the same thing as “a recommended dose.” They tested the same daily activity amount, but selected different participants, followed them for different periods, and asked different questions. [2] [3]
Swipe to compare →
| Study feature | Kim et al., 2008 | Hodis et al., 2021 |
|---|---|---|
| Design | Randomized, double-blind, placebo-controlled | Randomized, double-blind, placebo-controlled |
| Participants | 86 randomized; 73 completed | 265 randomized; median age 65.3 years |
| Starting population | Ages 20–80; untreated systolic blood pressure of 130–159 mmHg | Adults without clinical evidence of cardiovascular disease |
| Daily amount | 2,000 FU | 2,000 FU |
| Duration | 8 weeks | Median 3 years of randomized treatment |
| Reported finding | Lower blood-pressure changes relative to placebo | No significant difference in carotid thickness or stiffness progression; no significant effect on blood pressure or laboratory measurements |
| Source | 2008 study abstract | 2021 study abstract |
What the eight-week blood-pressure result actually says
In the 2008 trial, the net changes relative to the control group were −5.55 mmHg for systolic pressure and −2.84 mmHg for diastolic pressure after eight weeks. Both reported 95% confidence intervals excluded zero, although they were fairly wide. [2]
Swipe to compare →
| Outcome | Net change vs. placebo | 95% confidence interval |
|---|---|---|
| Systolic blood pressure | -5.55 mmHg | -10.5 to -0.57 mmHg |
| Diastolic blood pressure | -2.84 mmHg | -5.33 to -0.33 mmHg |
The negative signs indicate lower changes relative to placebo; they are not a promise that each participant experienced that reduction. The intervals describe statistical uncertainty around the estimated group difference, not a range of results that each individual user should expect.
Why the three-year result also belongs in the article
The 2021 study found no significant difference in the annualized progression of carotid intima-media thickness or carotid arterial stiffness. It also found no significant effect on blood pressure or laboratory determinations. [3] Its trial registration describes the planned comparison of oral 2,000 FU daily against placebo. [7]
These findings do not support a blanket promise for 2,000 FU. They also do not establish that 4,000 FU would have performed better: the trial did not test that comparison. Keeping both studies visible avoids selecting only the favorable result.
What Japanese research adds—and what it cannot establish
A Japanese human study adds a different kind of evidence to the 2,000-FU discussion: short-term changes in blood measurements after a single intake. It does not answer the same question as the eight-week blood-pressure trial or the three-year trial above.
Kurosawa and colleagues' 2015 study involved 12 healthy young Japanese men. In a randomized, double-blind, placebo-controlled crossover design, each participant received a single 2,000-FU intake of the specified NSK-SD preparation and placebo on separate occasions, with a washout of more than two weeks. Blood was sampled over eight hours. [8]
Swipe to compare →
| Source | What it reports | What it does not establish |
|---|---|---|
| Kurosawa et al., 2015: human crossover trial | Some fibrinolysis and coagulation markers differed from placebo at specific time points, including D-dimer, fibrin/fibrinogen degradation products and activated partial thromboplastin time. All reported changes remained within normal ranges. | Long-term clinical benefit, fewer heart attacks or strokes, suitability for patients taking medication, or superiority of 4,000 over 2,000 FU. [8] |
| Japan Nattokinase Association: industry FAQ | The association recommends 2,000 FU per day and discusses FU-based activity measurement. | A government-established universal intake, an individualized prescription, or a head-to-head clinical dose comparison. [9] |
The distinction is important: a short-term blood-marker change is not a demonstrated reduction in clinical events. This small study of healthy young men did not establish long-term effectiveness or safety in older adults, people with cardiovascular disease, or people taking anticoagulant or antiplatelet medicines. Its specified preparation also cannot lend its findings to every retail product displaying 2,000 FU. The authors acknowledged Japanese KAKENHI research funding. [8]
The association's 2,000-FU recommendation explains a Japanese industry position, not an independently validated dose for everyone. Its FAQ also makes broad statements about efficacy and medication safety; those statements are not adopted here as clinical guidance. A Japanese source should be judged by its methods and evidence, not treated as stronger simply because it is Japanese. [9]
What a 2,000-FU label looks like: two product examples
The number also appears on retail labels. For example, the standard ORIHIRO Nattokinase product lists 2,000 FU per 3 capsules, while Kobayashi Nattokinase Sarasara Premium lists 2,000 FU per 6 capsules. These are examples of label arithmetic—not the trial preparations described above, and not suggestions to take the study amount. Manufacturer sources and full serving details are in the label comparison table.
Orihiro Nattokinase Capsules 60 Capsules
2,000 FU per 3 capsules, at manufacture. Package: 60 capsules.
Kobayashi Nattokinase Sarasara Premium 120 Capsules
2,000 FU per 6 capsules. Package: 120 capsules.
3. Does 4,000 FU—or More—Have Stronger Evidence?
A 2023 systematic review reports daily amounts ranging from 1,200 to 8,000 FU among its listed randomized trials. The chart below reproduces the amounts in that review's Table 1. It shows variation in study regimens, not variation in effectiveness. [1]
Swipe to compare →
| Trial listed in the review | Reported daily amount | Reported follow-up |
|---|---|---|
| Pham, 2020 | 1,200 FU | 60 days |
| Hodis, 2021 | 2,000 FU | 36 months |
| Jensen, 2016 | 2,000 FU | 8 weeks |
| Kim, 2008 | 2,000 FU | 8 weeks |
| Yoo, 2019 | 6,000 FU | 8 weeks |
| Yang, 2009 | 7,000 FU | 6 months |
| Wu, 2009 | 8,000 FU | 8 weeks |
Where does 4,000 FU fit?
The same review discusses a separate, eight-week, self-controlled study using 4,000 FU daily. It reports no obvious effects on lipid parameters in healthy volunteers or participants with cardiovascular risk factors. This was not a direct randomized comparison between 2,000 and 4,000 FU. [1]
“Self-controlled” means the participant's own earlier measurements serve as the comparison. Such a design can identify changes worth studying further, but without a concurrent randomized control group it cannot separate an intervention's contribution from all other changes over time.
What a 4,000-FU label looks like: four product examples
For a concrete label example, ORIHIRO Nattokinase 4000 lists 4,000 FU per 2 softgels. The same displayed activity appears on other products, but with a different number of units: 4 capsules for Noguchi HQ and Meiji Premium, or 8 tablets for FINE. These examples explain what “4,000 FU” refers to on a serving label; they do not link these retail products to the study's findings or establish who should take that amount.
Orihiro Nattokinase 4000 FU Dietary Supplement, 60 Softgels
4,000 FU per 2 softgels, at manufacture. Package: 60 softgels.
NOGUCHI MEDICAL RESEARCH INSTITUTE Nattokinase HQ 120 Capsules
4,000 FU per 4 capsules. Package: 120 capsules.
Meiji Kenko Kirari Nattokinase Premium 120 Capsules
4,000 FU per 4 capsules, at manufacture. Label serving: 2–4 capsules.
FINE Nattokinase 4000 FU Supplement, 240 Tablets
4,000 FU per 8 tablets, at manufacture. Package: 240 tablets.
Meiji's label permits a 2–4-capsule serving, but its published 4,000-FU figure is explicitly for 4 capsules. It should not be presented as 4,000 FU for every serving in that range. See the manufacturer-sourced table for the exact basis of each example.
What about the frequently cited 10,800-FU study?
A 2022 paper analyzed records from 1,062 participants over 12 months and reported improvements in blood lipids and carotid measurements. Its dose-comparison table lists 1,001 people at 10,800 FU daily and 61 at 3,600 FU daily. These were not groups assigned through a randomized placebo-controlled trial. [4]
The study selected records with the required measurements and use history. Some participants also used vitamin K2 or aspirin, and several authors disclosed employment with the preparation's manufacturer. Those details do not automatically invalidate the observations, but they matter when judging selection, confounding, and independence.
The authors themselves identify the retrospective design as a limitation and call for further randomized trials. The findings are therefore not a sound basis for telling readers to increase their intake to 10,800 FU. A large participant count does not remove the need for a suitable comparison group. [4]
A source-quality detail worth knowing: the 2023 review's abstract reports six studies and 546 participants, while Table 1 lists seven trials whose group counts total 607. We do not use the abstract's pooled count as an unquestioned headline. The chart is explicitly based on the table; conclusions about dose suitability remain uncertain. [1]
4. Why There Is No Reliable “Dose by Type of Person” Chart
It is reasonable to ask whether age, blood pressure, or another health factor changes which amount is suitable. However, the evidence above does not establish a dependable way to assign a personal dose.
A trial enrolling people with elevated blood pressure tells us who was studied. It does not prove that every person with elevated blood pressure should use the study amount. Likewise, a trial with older adults does not establish an age-based dosing rule. The 2023 review considers its findings preliminary and says definitive conclusions about cardiovascular risk-factor improvements cannot be drawn. [1]
Swipe to compare →
| Evidence type | Useful question | Important boundary |
|---|---|---|
| Placebo-controlled randomized trial | Did the assigned regimen differ from placebo on specified outcomes? | Results remain tied to the tested preparation, participants, duration, and endpoints |
| Before-and-after study | Did measurements change during the observation period? | Change alone does not isolate the cause |
| Retrospective record analysis | What patterns appear in existing records? | Selection and other exposures can influence the pattern |
| Systematic review | What does the collected trial literature suggest? | Pooling does not repair every limitation or create an individualized dose rule |
A persuasive dose comparison would need appropriate head-to-head randomized groups, adequate follow-up, carefully defined populations, relevant endpoints, and safety assessment. We cannot assemble those conditions merely by putting separate 2,000- and 4,000-FU studies beside each other.
The useful distinction: “2,000 FU was studied in these participants” is a factual description. “2,000 FU is suitable for people like you” is a recommendation that the cited research does not establish.
5. Compare Labels Without Turning FU into a Benefit Ranking
Once FU is understood, shopping comparisons become more practical: check the complete serving, the form, other ingredients, and product-specific directions. Two products can show the same FU figure while using quite different serving sizes and formulas.
Here is the serving-size context for the six illustrated Japan Pantry products, checked against their manufacturers' specifications. The table reports label facts, not an effectiveness ranking. It does not claim that these products were tested in, or reproduce the results of, the cited trials.
Swipe to compare →
| Product example | Published activity and its denominator | Manufacturer's serving and important qualification | Label source |
|---|---|---|---|
| ORIHIRO Nattokinase, 60 capsules | 2,000 FU per 3 capsules | 3 capsules; activity stated at manufacture | ORIHIRO specification |
| Kobayashi Sarasara Premium, 120 capsules | 2,000 FU per 6 capsules | 6 capsules; do not interpret the package count as the serving | Kobayashi specification |
| ORIHIRO Nattokinase 4000, 60 softgels | 4,000 FU per 2 softgels | 2 softgels; activity stated at manufacture | ORIHIRO specification |
| Noguchi Nattokinase HQ, 120 capsules | 4,000 FU per 4 capsules | 4 capsules; the FU figure is for the complete serving | Noguchi specification |
| Meiji Kenko Kirari Premium, 120 capsules | 4,000 FU per 4 capsules | 2–4 capsules; the 4,000-FU figure applies to 4 capsules, at manufacture | Meiji specification |
| FINE Nattokinase 4000, 240 tablets | 4,000 FU per 8 tablets | 8 tablets; activity stated at manufacture | FINE specification |
Notice the denominator: these are figures for the specified number of capsules, softgels, or tablets—not for a single unit. Similar displayed activity numbers do not make the formulas identical. For example, FINE also lists coenzyme Q10, quercetin, garlic extract, and vitamins, whereas ORIHIRO 4000 lists DHA, EPA, DPA, rutin, and hesperidin. That is a legitimate label comparison; it is not proof that their clinical effects are identical.
The serving counts above quote the manufacturers' labeling; they are not dosing instructions from this article. Match the exact product version and read the current package, ingredients, and cautions before making any intake decision.
For a broader overview of Japanese brands and formats, read our Japanese nattokinase supplement buying guide. Use the current package and product-specific cautions alongside the page, and do not change your intake solely to match a research number.
6. Safety Questions Come Before Choosing a Number
The systematic review reports no major adverse events in its included trials, while also discussing case reports involving bleeding or allergic concerns. Limited trial samples and follow-up cannot reliably exclude uncommon harms. The absence of a reported major event is not evidence of universal safety. [1]
One manufacturer label archived in the NIH Dietary Supplement Label Database instructs people taking medication, including anticoagulants, or with a medical condition to consult a physician before use. It also excludes pregnant or nursing users and children. This is a manufacturer's product label in an NIH archive—not an NIH clinical dosing recommendation or a warning automatically identical across all brands. [6]
A separate case report describes a person with a mechanical aortic valve who replaced prescribed warfarin with nattokinase and subsequently developed valve thrombosis requiring repeat surgery. It documents substitution, not the risk of taking the two together, and cannot quantify an interaction or its frequency. It is a clear reason not to substitute a supplement for prescribed anticoagulation. [5]
If you take an anticoagulant or antiplatelet medicine, have a bleeding-related condition, or have an upcoming procedure, discuss supplement use with your treating clinician before deciding on an amount. The studies in this article do not provide a personal dosing rule for those circumstances, pregnancy, breastfeeding, or children.
Frequently Asked Questions
Is 4,000 FU necessarily better than 2,000 FU?
No. A larger stated activity number does not establish a better individual outcome. The studies summarized here are not a reliable head-to-head test of those two amounts in the same population.
Is 2,000 FU a proven standard amount for everyone?
No. It is an amount used in several trials. The eight-week blood-pressure trial and the three-year trial produced different findings in different participants. A studied regimen is not a universal recommendation. [2] [3]
Can I choose a dose by age or blood pressure?
Not from the cited evidence. Participant age and eligibility describe the study population; they do not establish a validated personal-dose calculator.
Does the 10,800-FU paper justify taking more?
It does not provide randomized evidence that this is an optimal personal amount. It is a retrospective analysis, with unequal dose groups and other exposures that complicate attribution. [4]
Can nattokinase replace prescribed anticoagulation?
Do not stop or replace prescribed medication on the basis of a supplement label or this article. The mechanical-valve case report illustrates a serious consequence of self-substitution. [5]
Bottom line: use FU to understand a label's stated enzyme activity—not to rank clinical benefit or prescribe a personal dose. Compare actual serving details, read positive and negative findings together, and keep medication decisions with your clinician.
Sources and Reading Notes
- Li et al. (2023). Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reviews in Cardiovascular Medicine, 24(8), 234. Table 1 supplies the chart data; the discussion describes the separate 4,000-FU study and evidence limitations. Note the abstract/table count discrepancy discussed above.
- Kim et al. (2008). Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertension Research, 31(8), 1583–1588. PMID: 18971533. Source for the 86 randomized participants, 73 completers, eight-week regimen, estimates, and confidence intervals.
- Hodis et al. (2021). Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clinical Hemorheology and Microcirculation. PMID: 33843667. Source for the 265-person, 2,000-FU, median-three-year trial and its null findings.
- Chen et al. (2022). Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Frontiers in Cardiovascular Medicine, 9, 964977. This is the published title, not a product claim. Read the methods, dose-group Table 6, limitations, and employment disclosures alongside the authors' findings.
- Elahi et al. (2015). Consequence of patient substitution of nattokinase for warfarin after aortic valve replacement with a mechanical prosthesis. Proceedings (Baylor University Medical Center), 28(1), 81–82. A single case report about replacement of prescribed anticoagulation, not a dose-efficacy trial.
- NIH Dietary Supplement Label Database: archived Vitamin Shoppe nattokinase product label. Manufacturer-label example, not an independent clinical guideline. Its cautions must not be attributed to NIH as medical recommendations.
- ClinicalTrials.gov: Nattokinase Atherothrombotic Prevention Study, NCT02080520. Registration describing the planned randomized 2,000-FU daily comparison and eligibility. Use the published 2021 paper for final participant numbers and results.
- Kurosawa et al. (2015). A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Scientific Reports, 5, 11601. DOI: 10.1038/srep11601. The published title is not a retail-product claim. Original methods and results describe 12 healthy Japanese men, a single 2,000-FU preparation, an eight-hour observation window and changes within normal ranges; acknowledgments identify KAKENHI funding.
- Japan Nattokinase Association: Nattokinase FAQ (Japanese). Industry-association source, checked October 5, 2026. Cited only for its own 2,000-FU recommendation and activity-measurement context, not as government advice, independent efficacy evidence or medication-safety guidance.
The tables distinguish trial findings, review-reported information, and retail label facts. No findings here establish a reduced rate of heart attacks or strokes, an optimal dose for a specific person, or the efficacy of the linked retail products.
